SYLVIA BUSTAMANTE: Open Payments
NPI 1891980223 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,581 in 65 payments from 10 companies in 2025. Trend: 2023 $733 · 2024 $1,060 · 2025 $1,581
Food & beverage: $1,581
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 13 | $478 |
| Novo Nordisk Inc | 15 | $293 |
| Lilly USA, LLC | 15 | $293 |
| ABBVIE INC. | 7 | $156 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $145 |
| PFIZER INC. | 3 | $76 |
| Exact Sciences Corporation | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Amgen Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $21 |
Products named: FREESTYLE LIBRE 3, Wegovy, XIFAXAN, ZEPBOUND, MOUNJARO, ELIQUIS, VRAYLAR, JARDIANCE.
Industry payments across TX — which companies pay providers there.
